Jeffrey A. Bluestone, Ph.D.A.W. and Mary Margaret Clausen Distinguished Professor, and Director, Hormone Research Institute, University of California, San Francisco
Dr. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute at the University of California, San Francisco (UCSF). Dr. Bluestone is one of the leading immunologists in the field of T-cell activation, co-stimulation, and immune tolerance research that has led to the development of multiple pro-tolerogenic immunotherapies including: CTLA4Ig (the first U.S. Food and Drug Administration-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation), a novel anti-human CD3 antibody being developed to treat Type 1 diabetes (T1D), and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. Dr. Bluestone’s recent research has focused on the critical role of regulatory T cells (Tregs) in autoimmunity. He has shown that Tregs are key in the control of immune homeostasis but unstable in autoimmune diseases such as T1D and multiple sclerosis. He has spearheaded the use of Tregs as a cell-based therapy to treat T1D and organ transplantation. Finally, Dr. Bluestone is an academic leader on a national and international scale. He was the founder and first Director of the Immune Tolerance Network (ITN), the largest National Institutes of Health-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy.
Irun R. Cohen, M.D.Professor Emeritus of Immunology, Weizmann Institute of Science
Dr. Cohen is a Professor Emeritus of Immunology at the Weizmann Institute of Science in Rehovot, Israel, where he served as director of the Robert Koch-Minerva Center for Research in Autoimmune Diseases. Dr. Cohen also served as director of the Center for the Study of Emerging Diseases in Jerusalem, Israel. He is the inventor of T cell vaccination therapy for autoimmune disease, now in clinical trials with fast-track designation by the U.S. Food and Drug Administration. He is co–founder and scientific advisor of Alma Bio Therapeutics in Lyon, France. Dr. Cohen received his M.D. from Northwestern University, where he also received his B.A. in philosophy; he specialized in pediatrics at Johns Hopkins University.
Charles A. Dinarello, M.D.Professor of Medicine and Immunology, University of Colorado School of Medicine
Dr. Dinarello is Professor of Medicine and Immunology at the University of Colorado School of Medicine, and Professor of Experimental Medicine at Radboud University in the Netherlands. Dr. Dinarello received his medical degree from Yale University School of Medicine, completed his clinical training at the Massachusetts General Hospital, and from 1971 to 1977 he was an investigator at the National Institutes of Health. Dr. Dinarello is considered one of the founding fathers of cytokine research. He identified interleukin1α (IL1α) in 1974 and was the first to purify IL1β in 1977. His group reported the first cDNA for IL-1β in 1984. Dr. Dinarello has published over 700 original research articles and 250 reviews, editorials and book chapters. He has trained over 50 investigators, many of whom are recognized experts in their fields. The Institute for Scientific Information listed Dr. Dinarello as the world’s fourth most-cited scientist during the 20 years 1983-2002 and from 1996 to 2011, he was listed as one of 400 of the world’s most influential biomedical researchers.
Dr. Dinarello was elected to the National Academy of Sciences in 1998 and was made a foreign member of the Royal Netherlands Academy of Sciences in 2010. He is a member of the Board of Governors of the Weizmann Institute (Israel) and Ben-Gurion University (Israel) and former Vice President of the American Society for Clinical Investigation and President of the International Cytokine Society. He has received honorary degrees from the University of Marseille (France), the Weizmann Institute (Israel), the University of Frankfurt (Germany), Roosevelt University (USA), Albany Medical College (USA), Radboud University (Netherlands), Trinity College (Ireland), and the University of Bonn (Germany).
Dr. Dinarello has received numerous awards for his contributions to the field of cytokines and medicine, including the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol-Nachman Prize (Germany), Sheikh Hamdan bin Rashid al Maktoum Award (United Arab Emirates), Beering Award (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland), Bonazinga Award (USA), the Lifetime Achievement Award of the Eicosanoid Research Foundation (USA), and the Drexel Prize in Immunology (USA). Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports cytokine research by young investigators.
Arnold J. Levine, Ph.D.Professor Emeritus, School of Natural Sciences, Institute for Advanced Study, Princeton, NJ
Dr. Levine is a Professor Emeritus of the School of Natural Sciences and founder of the Simons Center for Systems Biology at the Institute for Advanced Study in Princeton, NJ. Previously, he was the Robert and Harriet Heilbrunn Professor of Cancer Biology and President of Rockefeller University. He is the co-founder of PMV Pharma. Dr. Levine discovered the p53 tumor suppressor protein, an achievement for which he has received several awards, including the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research. Dr. Levine received his Ph.D. in microbiology from the University of Pennsylvania and trained as a postdoctoral fellow at the California Institute of Technology. He received his B.A. in biology from Binghamton University.
Daniel R. Littman, M.D., Ph.D.Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Skirball Institute of Biomolecular Medicine, NYU Langone Medical Center
Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator of the Howard Hughes Medical Institute. Prior to joining NYU in 1995, Dr. Littman was Professor of Microbiology and Immunology at the University of California, San Francisco. Dr. Littman’s laboratory applies molecular and genetic tools to study specification of T lymphocyte lineages, the differentiation of inflammatory lymphoid cells, and the mechanism of HIV interaction with the host innate immune system. Dr. Littman is a member in the National Academy of the Sciences and the Institute of Medicine, and is a fellow in the American Academy of Arts and Sciences and the American Academy of Microbiology. Dr. Littman is a Founding Scientific Advisory Board Member of Vedanta Biosciences and serves as a Member of Scientific Advisory Boards at ChemoCentryx, Inc., the Cancer Research Institute, and the Institute of Molecular Pathology in Vienna. Dr. Littman was awarded the 2004 New York City Mayor’s Award for Excellence in Science and Technology and the 2013 Ross Prize in Molecular Medicine. Dr. Littman completed the M.D./Ph.D. program at Washington University in St. Louis, where he worked with Benjamin Schwartz and Susan Cullen on the function of histocompatibility molecules in antigen presentation. Dr. Littman completed postdoctoral research under Richard Axel at Columbia University, where he isolated the genes for the immune signaling molecules CD4 and CD8. Dr. Littman received his A.B. in biochemical sciences from Princeton University.
David W.C. MacMillan, Ph.D.James S. McDonnell Distinguished Professor of Chemistry, Princeton University
Dr. MacMillan is the James S. McDonnell Distinguished Professor of Chemistry and Chair of the Department of Chemistry at Princeton University. He is also Director of the Merck Center for Catalysis at Princeton. Dr. MacMillan is co-founder of Chiromics, a company that generates chemical compound libraries. Dr. MacMillan received his Ph.D. under Professor Larry E. Overman at the University of California, Irvine and completed his postdoctoral research fellowship under Professor David A. Evans at Harvard University. Dr. MacMillan received his undergraduate degree in chemistry from the University of Glasgow.
Peter Palese, Ph.D.Professor and Chair, Department of Microbiology, Mount Sinai Medical Center
Dr. Palese is the Horace W. Goldsmith Professor of Medicine in Infectious Diseases and Professor and Chair of the Department of Microbiology at Icahn School of Medicine at Mount Sinai. Dr. Palese is a member of the National Academy of Sciences (NAS), the Institute of Medicine (IOM) and the American Academy of Arts and Sciences (AAAS). Dr. Palese is a co-founder of Vivaldi Biosciences and Aviron. Dr. Palese’s research is on RNA containing viruses with emphasis on influenza viruses.
Joshua Rabinowitz, M.D., Ph.D.Professor of Chemistry and Integrative Genomics, Princeton University
Dr. Rabinowitz is a Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. He is a Member of the Rutgers Cancer Institute of New Jersey. Dr. Rabinowitz is a co-founder of Alexza Pharmaceuticals, where he invented the Adasuve® Inhaler, which is approved in the United States and Europe for treatment of acute agitation. Dr. Rabinowitz has served as Chief Scientist and acting-CEO at NJOY, Inc and is a co-founder of Raze Therapeutics. Dr. Rabinowitz received his M.D. from Stanford University, where he also received his Ph.D. in biophysics. He received his B.A. in mathematics and chemistry from the University of North Carolina at Chapel Hill.
Neal Rosen, M.D., Ph.D.Director, Center for Mechanism Based Cancer Therapies, Memorial Sloan Kettering Cancer Center
Dr. Rosen is Director of the Center for Mechanism-Based Cancer Therapeutics at Memorial Sloan Kettering Cancer Center, where he is also a Member in the Molecular Pharmacology and Chemistry Program and the incumbent of the Enid A. Haupt Chair in Medical Oncology. Dr. Rosen is also a Professor of Pharmacology, Cell Biology and Medicine at Weill Cornell Medical College. His research interests include the identification and study of key molecular events and growth signaling pathways responsible for the development of cancer and the use of this information to develop mechanism-based therapeutic strategies. Dr. Rosen has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and has pioneered the concept that cancer cells are dependent on cellular machinery for protein folding. Dr. Rosen received his M.D. from the Albert Einstein School of Medicine, where he also received his Ph.D. in molecular biology. He received his B.A. in chemistry from Columbia University.
Robert Schneider, Ph.D.Albert B. Sabin Endowed Chair for Molecular Pathogenesis, NYU School of Medicine
Dr. Schneider is the Albert B. Sabin Professor of Molecular Pathogenesis at the NYU School of Medicine; he is also an Associate Director of the NYU Cancer Institute, Director of Translational Cancer Research, Co-Director of the Breast Cancer Program and a Professor of Radiation Oncology. In 2013, he became the inaugural Associate Dean for the new Office of Therapeutics and Industry Alliances at NYU Langone Medical Center. Dr. Schneider performs basic, translational and clinical research on the molecular basis of locally advanced, metastatic and inflammatory breast cancers and the development of new therapeutics. He is the author of more than 140 peer-reviewed publications in oncology and inflammation and has received numerous awards and prizes in recognition of his achievements. Dr. Schneider is a co-founding scientist of five biotechnology/small pharmaceutical companies: ImClone Systems, PTC Therapeutics Inc., Canji, Gencell (Paris), and Charterhouse Pharmaceuticals (London). Dr. Schneider received his Ph.D. in biomedical sciences from the Icahn School of Medicine at Mount Sinai and was a postdoctoral research fellow in the Department of Microbiology at Stony Brook University. He completed additional postdoctoral training in the Department of Molecular Biology at Princeton University.
Thomas E. Shenk, Ph.D.James A. Elkins Jr. Professor of Life Sciences, Department of Molecular Biology, Princeton University
Dr. Shenk has served as a member of our Board of Directors since 2014 and he has served as a member of Kadmon’s Scientific Advisory Board since December 2013. Dr. Shenk has been the James A. Elkins Jr. Professor of Life Sciences in the Department of Molecular Biology at Princeton University since 1984. Dr. Shenk is a fellow of the American Academy of Arts and Sciences and a member of the U.S. National Academy of Sciences and the National Academy of Medicine. Dr. Shenk serves as the Chairman of the Board of MeiraGTx Limited. He is a past president of the American Society for Virology and the American Society for Microbiology and served on the board of Merck and Company from 2001 to 2012. Dr. Shenk currently serves as a board member of the Hepatitis B Foundation. Dr. Shenk received his B.S. from the University of Detroit and his Ph.D. from Rutgers University.
Theodore Tyberg, M.D.Associate Attending Physician, NewYork-Presbyterian Hospital
Dr. Tyberg has been a cardiologist at NewYork-Presbyterian Hospital and New York Cardiology Associates for the past 34 years. He attended the City College of New York and graduated Alpha Omega Alpha from Rush University Medical College in Chicago. Dr. Tyberg completed his internship and residency at NewYork-Presbyterian Hospital, Weill Cornell Medical Center and his fellowship in cardiology at Yale University Medical Center.
Dr. Tyberg is the co-author of Hospital Smarts, a patient-oriented guide to hospitalization. He is Secretary/Treasurer of the New York State chapter of the American College of Cardiology. He is a Clinical Associate Professor at Weill Cornell Medical College and Associate Attending Cardiologist at New York-Presbyterian Hospital. He is the cardiology consultant for The Rogosin Institute Comprehensive Lipid Control Center.
Dr. Tyberg is on the Board of Governors of the Center Alumni Council, has been president of the attending staff at NewYork-Presbyterian Hospital and a delegate on the general faculty council.